A 14-year retrospective analysis of indications and outcomes of autologous haemopoietic stem cell transplantation in regional Queensland: a single-centre experience

Hamilton, Elizabeth M., Nath, Karthik D., Vangaveti, Venkat N., McCutchan, Andrew D., Marsh, Jodie L., Birchley, Andrew J., Casey, John M., McNamara, Caroline, Lai, Hock C., Morris, Edward S., Hodges, Georgina, and Irving, Ian M. (2020) A 14-year retrospective analysis of indications and outcomes of autologous haemopoietic stem cell transplantation in regional Queensland: a single-centre experience. Internal Medicine Journal, 50 (2). pp. 214-221.

[img] PDF (Published Verison) - Published Version
Restricted to Repository staff only

View at Publisher Website: https://doi.org/10.1111/imj.14395
 
1


Abstract

Background: The Townsville Hospital is a tertiary hospital in North Queensland with one of the largest regional transplant centres in Australia, performing primarily autologous haemopoietic stem cell transplants (HSCT) for various haematological malignancies.

Aims: This single-centre, retrospective, observational study aims to describe the activity and outcomes of autologous HSCT at The Townsville Hospital between 2003 and 2017 to verify safety standards.

Methods: Patient-level data were collected, including demographics, frequency and indication for transplant, conditioning, current clinical status and cause of death. Key outcomes included overall survival, non-relapse mortality, incidence of therapy-related neoplasm and causes of death. Progression-free survival in the multiple myeloma (MM) subgroup was also assessed.

Results: There were 319 autologous HSCT in 286 patients, with a median age of 58 years (range 14-71 years); 62% of patients were male. Indications for transplantation were: MM 53.7%, non-Hodgkin lymphoma 29.4%, Hodgkin lymphoma 5.0% and other 11.9%. Causes of death were: disease progression/relapse (65.2%), second malignancy (17.0%), infection (9.8%) and other (8.0%). Non-relapse mortality was 1.2% (95% confidence interval 0.4-3.0) and 3.2% (1.7-5.7) at 100 days and 1 year, respectively, post-HSCT. Overall survival at 2 years was 81.0% (73.8-86.4) for MM and 69.6% (58.8-78.1) for non-Hodgkin lymphoma. The median progression-free survival in the MM cohort was 3.3 years.

Conclusion: The Townsville Hospital transplant centre provides an important transplant service in regional Queensland, with outcomes comparable to national data. We reported a relatively high rate of second malignancy as a cause of death.

Item ID: 63202
Item Type: Article (Research - C1)
ISSN: 1445-5994
Keywords: haemopoietic stem cell transplantation, myeloma, lymphoma, Australia
Copyright Information: © 2019 Royal Australasian College of Physicians
Date Deposited: 20 May 2020 07:32
FoR Codes: 11 MEDICAL AND HEALTH SCIENCES > 1112 Oncology and Carcinogenesis > 111206 Haematological Tumours @ 40%
11 MEDICAL AND HEALTH SCIENCES > 1112 Oncology and Carcinogenesis > 111201 Cancer Cell Biology @ 30%
10 TECHNOLOGY > 1004 Medical Biotechnology > 100404 Regenerative Medicine (incl Stem Cells and Tissue Engineering) @ 30%
SEO Codes: 92 HEALTH > 9201 Clinical Health (Organs, Diseases and Abnormal Conditions) > 920102 Cancer and Related Disorders @ 50%
92 HEALTH > 9201 Clinical Health (Organs, Diseases and Abnormal Conditions) > 920108 Immune System and Allergy @ 50%
Downloads: Total: 1
Last 12 Months: 1
More Statistics

Actions (Repository Staff Only)

Item Control Page Item Control Page